Poria Cocos Formulas: Clinical Evidence Across 5 Conditions

Poria in TCM Formulas

12 randomized trials

Wang's 2021 meta-analysis of 12 randomized controlled trials found Si Jun Zi Tang-based therapies significantly outperformed conventional medicine for functional dyspepsia, though the benefit centered on modified formulations. It is the strongest clinical evidence for any Poria-based formula.

Wang et al., BMC Complement Med Ther, 2021

800mg nightly

Poria extract dose that added roughly 29 minutes of sleep in a 2023 clinical study (Nutrients)

Top 10

Poria ranks among China's 10 most prescribed herbs for type 2 diabetes in formula combinations

RCT confirmed

Wu Ling San's diuretic effect was confirmed in a placebo-controlled trial (Lin 2013)

Wang et al., BMC Complement Med Ther, 2021

View as image ↗

Poria cocos (Fu Ling) appears in hundreds of classical Chinese herbal formulas, but how many of those formulas have been tested in modern clinical research? More than most consumers realize; far fewer than TCM advocates sometimes claim. The Poria cocos formula clinical evidence base ranges from an impressively large meta-analysis down to preliminary laboratory work, depending on which condition you're looking at.

This article is part of the broader guide on what Poria is and why it became central to Chinese medicine. The focus here is strictly on what modern clinical and preclinical research has confirmed, organized by condition and ranked by evidence quality.

The table below summarizes the strongest evidence for each application area:

Evidence Review

1. Cell studiescompleted

   Extensive: triterpenoids and polysaccharides characterised in vitro

2. Animal studiescompleted

   The majority of Poria research still sits here (2026 narrative review)

3. Small human trialscompleted

   Wu Ling San diuresis RCT (28 completers); Poria sleep study (21 participants)

4. Large / multiple RCTscompleted

   73-RCT diabetes review; 13-RCT ovarian-cancer meta-analysis

5. Meta-analysiscurrent

   Si Jun Zi Tang: 12-RCT meta-analysis for functional dyspepsia

For its best-studied formula, Si Jun Zi Tang, Poria evidence reaches meta-analysis level. For most other conditions it remains at the animal-model and small-trial rungs, which is why the evidence quality varies so much by application.

Wang 2021; Di 2022; Peng 2022; Guo 2026

Digestive Disorders: Si Jun Zi Tang Backed by 12 Randomized Controlled Trials

Si Jun Zi Tang, which translates as "Four Gentlemen Decoction," is one of the oldest and most studied formulas in Chinese medicine. It combines Poria with ginseng (Ren Shen), white atractylodes (Bai Zhu), and licorice root (Zhi Gan Cao) in a formula specifically designed for what TCM calls "Spleen Qi deficiency," a pattern characterized by poor digestion, fatigue, and loose stools that maps closely to the modern diagnosis of functional dyspepsia.

In 2021, Wang and colleagues published a meta-analysis in BMC Complementary Medicine and Therapies that searched seven databases for randomized controlled trials of Si Jun Zi Tang for functional (non-ulcer) dyspepsia. Of 341 records screened, twelve trials met the inclusion criteria. Pooled analysis found that Si Jun Zi Tang-based therapies produced a significantly higher response rate than conventional western medicine (relative risk 1.23; 95% CI 1.17 to 1.30) and a lower relapse rate (odds ratio 0.23). Notably, the response-rate benefit was concentrated in modified Si Jun Zi Tang formulations rather than the classical four-herb recipe.^[1]

This makes Si Jun Zi Tang the best-evidenced Poria formula by a wide margin. A 12-trial meta-analysis represents a level of evidence that most supplements and many single-herb products cannot match for their specific indications.

There are real caveats. The review's own authors rated every included trial at high risk of bias, and most were conducted in China, where trial registration and reporting standards have historically been variable. The primary outcome, "response rate," is a composite that combines different symptom assessments across studies. And the mechanism through which Poria specifically contributes to the formula's digestive effects is understood at the molecular level but not yet confirmed in head-to-head comparator trials.

For the mechanism: Poria's triterpenoids modulate inflammatory pathways that drive dyspeptic symptoms; its polysaccharides feed the gut microbiome organisms that produce short-chain fatty acids regulating gut motility. When these compounds work alongside ginseng's ginsenosides (which stimulate gastric secretion) and atractylodes' polysaccharides (which modulate gut transit), the formula plausibly addresses digestive dysfunction through multiple pathways simultaneously.

For a deeper look at how Poria's presence specifically changes the formula's activity, the article on how Poria enhances other herbs in traditional formulas covers the synergy mechanisms. The fuller historical and theoretical context for all these formulas is in the overview of classical Poria TCM formulas.

Kidney Stones and Fluid Retention: The Only Placebo-Controlled Trial

Wu Ling San, or "Five-Ingredient Powder with Poria," was first recorded in the Han Dynasty treatise Shang Han Lun, attributed to Zhang Zhongjing around 200 CE. It combines Poria with cinnamon twig (Gui Zhi), polyporus (Zhu Ling), alisma root (Ze Xie), and atractylodes (Bai Zhu). Its TCM indication is "water accumulation" (edema, difficult urination, and fluid imbalance), which maps to conditions including urinary dysfunction, edema, and metabolic fluid disorders.

Lin and colleagues conducted a prospective, randomized, placebo-controlled trial published in the African Journal of Traditional, Complementary and Alternative Medicines in 2013, specifically testing Wu Ling San's claimed diuretic effect.^[2]

Over one month, the formula significantly increased mean urine output: a 13.9% rise in the treatment group versus a 5.7% fall on placebo (p=0.02), with no reported electrolyte imbalance or side effects. This was a small trial. Thirty-nine patients enrolled and 28 completed it, split evenly between the Wu Ling San and placebo arms. Importantly, it measured diuresis, the mechanism by which the formula is thought to help prevent stone formation, rather than tracking actual stone-recurrence events over the long term. On the strength of these results the authors positioned Wu Ling San as a promising adjunct to standard surgical and medical management of kidney stones.

This trial is notable not just for what it found but for what it represents: a prospective placebo-controlled trial for a roughly 1,800-year-old formula. There are very few such trials for any classical herbal formula in any tradition, even if this one was small and short.

How does Wu Ling San produce its diuretic effect? Poria's contribution appears to come through two mechanisms. Its triterpenoids modulate aquaporin water channels in kidney tubule cells, the proteins that control how much water the kidney reabsorbs versus excretes, an effect demonstrated in laboratory studies of Poria's sclederma. Its polysaccharides show anti-inflammatory effects in kidney tissue. The other formula herbs are thought to reinforce these pathways: cinnamon twig's cinnamaldehyde activates heat-sensitive channels (TRPV1) that may improve renal blood flow; alisma and polyporus contain alisol compounds associated with increased urinary sodium excretion.

For readers interested in the specific Fu Ling and Gui Zhi combination that appears across multiple diuretic formulas, the article on the famous diuretic formula pair explores this combination in depth.

Sleep Quality: A 2023 Clinical Study Found Nearly 30 Extra Minutes of Sleep

The TCM use of Poria for calming the mind (an Shen) and improving sleep quality predates modern research by centuries. What is unusual is that this application has now been tested in a clinical setting.

A study published in the journal Nutrients in 2023 tested a Poria cocos extract (prepared with 75% ethanol) at 800mg nightly in 21 people with insomnia (mean age 55), measuring outcomes with a sleep questionnaire and objective overnight polysomnography.^[3]

Total sleep time rose significantly, from an average of 327 to 357 minutes (p=0.014), close to half an hour of additional sleep. Night-time arousal fell from 76 to 48 minutes (p=0.009), and participants' scores on the sleep-severity portion of the questionnaire improved. Because polysomnography measures brain activity directly rather than relying on self-report, these are unusually objective results for a natural sleep aid.

The dose and formulation matter. This was 800mg of a standardized 75%-ethanol extract nightly, not raw mushroom or powder, which concentrates the active compounds. The sample was small at 21 participants, so the finding should be read as promising rather than definitive. The study's authors singled out pachymic acid as a compound worth developing further as a sleep aid. Mechanistically, Poria's triterpenoids are thought to modulate GABA-A receptor activity, the same pathway through which benzodiazepine sleep medications work, but likely through a gentler, partial mechanism rather than the full agonism of pharmaceutical sedatives.

This sleep evidence is also directly relevant to understanding why Poria appears in formulas like Gui Pi Tang, a classical formula for "heart and spleen deficiency" that is used specifically for anxiety, rumination, and difficulty staying asleep. The clinical sleep data provides a pharmacological rationale for what TCM practitioners have been observing for centuries in formula use.

Type 2 Diabetes: Why Poria Is Among China's Top 10 Prescribed Herbs for Blood Sugar

A 2022 systematic review in PLOS ONE examined TCM formulas containing Poria cocos for type 2 diabetes management across the Chinese and English clinical literature. Poria ranks among the top 10 most frequently prescribed herbs in China for type 2 diabetes, a fact that reflects the accumulated clinical judgment of a massive practitioner base operating over decades. The review pooled 73 randomized controlled trials covering 6,489 patients and found that adding a Poria-containing formula on top of standard glucose-lowering drugs produced further reductions in fasting blood glucose and two-hour post-meal glucose compared with the drugs alone.^[4]

The proposed pharmacological mechanism runs through pachymaran, Poria's signature polysaccharide, and its triterpenoids. Laboratory studies suggest these compounds improve insulin sensitivity and glucose handling, with one proposed route being activation of AMPK, the cellular energy sensor that acts like a metabolic master switch. When AMPK is activated, cells become more responsive to insulin signals and more efficient at processing glucose. This is the same pathway targeted by metformin, the most widely prescribed diabetes medication globally, though the plant compounds and metformin activate AMPK through different molecular entry points.

The clinical evidence for Poria formulas in diabetes is not as clean as the numbers first suggest. The 2022 review pooled 73 randomized trials, but its authors judged most to be at risk of bias and graded the overall strength of evidence as low to moderate. The AMPK mechanism is well-characterized in laboratory and animal research; the human clinical translation is suggestive rather than definitive, and nearly all the trials were conducted in China.

Understanding why Poria works across these metabolic applications is clearer when you look at the underlying bioactive compounds. The article on Poria's bioactive compounds: pachymic acid, triterpenoids, and beta-glucans explains how each compound class maps to a specific pharmacological pathway. The pharmacology of Wolfiporia extensa covers the full mechanistic picture.

Cancer Support: What the Ovarian Cancer Evidence Actually Shows

The use of Poria-based formulas in cancer support represents both one of the most promising and most carefully-caveated areas of the clinical literature. A 2022 study in Frontiers in Pharmacology paired a meta-analysis of 13 randomized controlled trials (922 ovarian-cancer patients) with network pharmacology and laboratory experiments to evaluate Poria-based formulas added to chemotherapy.^[5]

Pooling the trials, Poria-based formulas added to paclitaxel-carboplatin (a platinum-based regimen) significantly improved tumour response rate, Karnofsky performance status, physical and social function, and quality of life, while reducing chemotherapy side effects, compared with chemotherapy alone. The mechanistic work pointed to the PI3K/AKT signalling pathway and the anti-apoptotic protein BCL2L1, with the triterpenoid tumulosic acid identified as the most active Poria compound and shown to induce cancer-cell apoptosis in laboratory experiments.

A 2019 review by Li and colleagues in Progress in Molecular Biology and Translational Science set out the broader molecular basis: Poria cocos polysaccharide, which makes up the bulk of the dried sclerotium, shows antitumour and immunomodulatory activity in laboratory studies, including effects on immune-cell function that could plausibly support the body's response to cancer during treatment.^[6]

The important caveats: although 13 randomized trials sounds substantial, they enrolled 922 patients in total, most were conducted in China, and trial quality varied. The network-pharmacology and cell-culture components generate mechanistic hypotheses rather than proof. This is genuine clinical signal, but not the settled, replicated evidence that would justify changing any treatment plan.

Medical Safety

Moderate

Cancer patients should not self-treat with Poria formulas

Concern

Poria-based formulas showed benefit only as an adjunct to standard paclitaxel-carboplatin chemotherapy in these trials, and herb-drug interactions during cancer treatment can be serious.

What the research says

Any use of Poria or TCM formulas during cancer care should be reviewed and supervised by the treating oncology team, not started independently.

Particularly relevant for: People undergoing or planning cancer treatment

What to do

Discuss any herbal supplement with your oncologist before use. This article is not medical advice.

Peng et al., Front Pharmacol, 2022

This is an active research direction, not a settled clinical application. Patients undergoing cancer treatment should not adjust their treatment protocol based on any individual study in this area.

The Honest Assessment: Most Poria Evidence Is Still Preclinical

The most current synthesis of the Poria evidence base is a 2026 narrative review published in Frontiers in Nutrition, which provides an explicit and useful assessment of where the field stands.^[7]

Its conclusion is candid: the majority of Poria research remains in cell cultures and animal models. The sleep clinical study and the Wu Ling San diuresis RCT represent the clearest controlled human evidence for specific outcomes. The Si Jun Zi Tang meta-analysis is stronger still for that specific formula, but the formula contains four herbs, so attributing the effects specifically to Poria's contribution (versus ginseng's, or atractylodes') requires caution.

What the 2026 review flags as the field's primary challenge is the same challenge facing all multi-herb formula research: when a formula works, you cannot easily determine which herb is doing the work. Poria might be a genuine contributor in every one of the five conditions covered here. It might be carrying the majority of the therapeutic load in some. In others, it might be providing safety and tolerability benefits (through its hepatoprotective and anti-inflammatory properties) while other formula herbs drive the primary effects.

The evidence says Poria-based formulas produce measurable outcomes in clinical settings for digestive disorders, fluid metabolism, and sleep quality. The evidence does not yet clearly establish Poria's individual contribution to those outcomes in multi-herb contexts.

For readers comparing Poria's evidence base to other TCM mushrooms, the centuries of documented Auricularia use in Chinese medicine provides a parallel picture of how another major TCM fungal ingredient has been used and studied. For the full catalogue of formulas that contain Poria, the guide to the most important TCM formulas containing Poria covers each formula's composition and indication in detail.

The Bottom Line

The strongest Poria cocos formula clinical evidence comes from a 12-RCT meta-analysis for Si Jun Zi Tang in functional dyspepsia, a small placebo-controlled diuresis trial for Wu Ling San, and a clinical study showing objective sleep improvements at 800mg nightly. Diabetes evidence is actually substantial, resting on a 73-RCT systematic review, while cancer support rests on a 13-RCT meta-analysis paired with mechanistic modelling. A 2026 narrative review honestly characterizes most Poria research as still preclinical, with the digestive, diuretic, and sleep data representing the firmest human evidence. Across every application, the core interpretive challenge is that these are multi-herb formulas, so Poria's individual contribution is difficult to isolate.

Frequently Asked Questions

Is there evidence that Poria cocos formulas work?

Yes, at varying levels of quality depending on the condition. The strongest evidence is a meta-analysis of 12 randomized controlled trials supporting Si Jun Zi Tang for functional dyspepsia (Wang et al., 2021). A placebo-controlled RCT confirmed Wu Ling San's diuretic effect (Lin et al., 2013). A 2023 clinical study found 800mg of Poria extract nightly produced measurable sleep improvements. Diabetes evidence is broader than often assumed, resting on a 73-RCT systematic review, and ovarian-cancer support rests on a 13-RCT meta-analysis combined with mechanistic modelling. In every case the trials were mostly conducted in China and vary in quality.

What conditions are Poria-based TCM formulas used for today?

The five conditions with the most modern clinical research behind Poria-based formulas are: functional digestive disorders (Si Jun Zi Tang, meta-analysis-level evidence), fluid retention and stone prevention (Wu Ling San, RCT evidence for diuresis), sleep quality (Poria extract, clinical study), type 2 diabetes support (multiple formulas, 73-RCT review), and cancer treatment adjuvant support (Poria combinations with chemotherapy, 13-RCT meta-analysis plus network pharmacology). Traditional use extends much further, but evidence quality varies considerably.

Does Poria mushroom help with sleep?

A 2023 clinical study published in the journal Nutrients found that 800mg of a standardized Poria cocos extract nightly increased total sleep time from about 327 to 357 minutes (p=0.014) and cut night-time arousal from 76 to 48 minutes (p=0.009) in 21 people with insomnia, measured objectively by polysomnography. This is the clearest human clinical evidence for Poria's sleep-promoting properties, which TCM has applied through formulas like Gui Pi Tang for centuries. The proposed mechanism involves Poria's triterpenoids acting on GABA-A receptors, the same broad target as pharmaceutical sleep aids, though the sample was small.

What is the clinical evidence for Si Jun Zi Tang?

A 2021 meta-analysis by Wang and colleagues in BMC Complementary Medicine and Therapies pooled 12 randomized controlled trials and found Si Jun Zi Tang-based therapies significantly outperformed conventional western medicine for functional (non-ulcer) dyspepsia, with a pooled response-rate relative risk of 1.23 and a lower relapse rate. The benefit was strongest for modified versions of the formula. This is relatively strong evidence by herbal-medicine standards, though the review's authors rated all included trials at high risk of bias, and most were conducted in China.

Do Poria formulas help with cancer treatment?

A 2022 study combined a meta-analysis of 13 randomized controlled trials (922 patients) with network-pharmacology modelling, finding that Poria-based formulas added to paclitaxel-carboplatin chemotherapy improved tumour response and quality of life in ovarian cancer, likely through the PI3K/AKT pathway and the protein BCL2L1. A 2019 molecular review by Li and colleagues described how Poria polysaccharides show antitumour and immune-modulating activity in the laboratory. This is a promising, mechanistically grounded research area, but the trials were mostly conducted in China and vary in quality, so it is not yet definitive. Cancer patients should never adjust treatment based on this evidence without oncology supervision.

Sources & References

1. 1RTHM-01453·Wang, Yaping et al. (2021). “Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials..” BMC complementary medicine and therapies.Study breakdown →PubMed →↩
2. 2RTHM-00540·Lin, Eugene et al. (2013). “Wu-Ling-San formula prophylaxis against recurrent calcium oxalate nephrolithiasis - a prospective randomized controlled trial..” African journal of traditional.Study breakdown →PubMed →↩
3. 3RTHM-01720·Kim, Hyeyun et al. (2023). “Efficacy of Poria Cocos Extract on Sleep Quality Enhancement: A Clinical Perspective with Implications for Functional Foods..” Nutrients.Study breakdown →PubMed →↩
4. 4RTHM-01503·Di, Yuan Ming et al. (2022). “Benefits of herbal formulae containing Poria cocos (Fuling) for type 2 diabetes mellitus: A systematic review and meta-analysis..” PloS one.Study breakdown →PubMed →↩
5. 5RTHM-01597·Peng, Xinya et al. (2022). “Efficacy and Pharmacological Mechanism of Poria cocos-Based Formulas Combined With Chemotherapy for Ovarian Cancer: A Integrated Systems Pharmacology Study..” Frontiers in pharmacology.Study breakdown →PubMed →↩
6. 6RTHM-01090·Li, Xiulian et al. (2019). “Molecular basis for Poria cocos mushroom polysaccharide used as an antitumor drug in China..” Progress in molecular biology and translational science.Study breakdown →PubMed →↩
7. 7RTHM-02230·Guo, Yanquan et al. (2026). “Research progress on the pharmacological effects of Poria cocos: a narrative update..” Frontiers in nutrition.Study breakdown →PubMed →↩